Trial to Evaluate Efficacy and Safety of Pembrolizumab and Gemcitabine in HER2-negative ABC

Advanced Breast Cancer Clinical Trial

— PANGEA  

Official title:

A Multicenter Phase II Trial to Evaluate the Efficacy and Safety of Pembrolizumab and Gemcitabine in Patients With HER2-negative Advanced Breast Cancer (ABC) "PANGEA-Breast"

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03025880
• Other study ID #: GEICAM/2015-04
• Secondary ID: 2016-001779-54
• Status: Completed
• Phase: Phase 2
• Start date: June 28, 2017
• Est. completion date: July 22, 2021

Study information

• Verified date: March 2023
• Source: Spanish Breast Cancer Research Group
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Study Design and Treatment:

This is a multicenter phase II trial, with an initial exploratory run-in-phase, to evaluate the efficacy and safety of pembrolizumab in combination with gemcitabine in patients with HER2-negative ABC that have previously received anthracyclines and taxanes (unless clinically contraindicated). In hormone receptor positive patients, previous treatment with 2 or more lines of hormone therapy will also be required. Patients must have at least one measurable lesion that can be accurately assessed at baseline and is suitable for repeated assessment by CT, MRI or plan X-ray. Approximately 53 patients (up to a maximum of 65 patients depending on the results of the run-in-phase) will be included in this trial.

Description:

Study Design and Treatment (continuation):

The study will include two cohorts of patients: i) Triple Negative and ii) Luminal A+B, with an approximate 1:1 distribution between both groups.

A safety dose testing or "run-in-phase", with a 6+6 design, in which toxicity will be evaluated within the first cycle, will be performed since pembrolizumab in combination with gemcitabine has not been previously tested. Initially 6 patients will be included in the study at dose level 0 (gemcitabine at a dose of 1,250mg/m2 as an IV infusion on day 1 and 8 of each 21-day cycle and pembrolizumab at a dose of 200mg as an IV infusion on day 1 of each 21-day cycle):

• If ≤ 2 patients experience Dose Limiting Toxicity (DLT), 6 additional patients will be included at the current dose level. If there is a confirmation of this dose to be safe (≤ 3 patients experiencing DLT), this will be considered the RP2D and it will be used for the following recruited patients.

• If ≥ 3 patients experience DLT within the first 6 patients, or ≥ 4 within the first 12 patients included at dose level 0, a de-escalation to dose level -1 (gemcitabine at a dose of 1,000mg/m2 as an IV infusion on day 1 and 8 of each 21-day cycle and pembrolizumab at a dose of 200mg as an IV infusion on day 1 of each 21-day cycle) will be performed. In this case, a group of 12 additional patients will be included at dose level -1, if ≥ 4 experience DLT, this combination will be considered too toxic and the study will be stopped. If ≤ 3 experience DLT with this combination, this will be considered the RP2D and it will be used for the following recruited patients.

Initially 3 patients will be allowed for inclusion simultaneously. These 3 patients will be followed closely during the first cycle to observe the occurrence of any DLT. At the times these 3 patients are completing the first cycle, the next 3 patients will be included one by one, until the first cohort is completed.

If none of these 6 patients have a DLT, up to 4 patients will be allowed for inclusion from the second cohort of 6 patients; they will follow the same procedure as in the first cohort. If one of these patients from the second cohort has a DLT, the inclusion will be in smaller groups (with a maximum number of 4 patients with DLT) and following the same procedure as in the first cohort of 6 patients.

An internal committee will periodically review the safety data in order to take the decision to maintain or decrease the dose level. This internal committee will consist of the chief investigator, the Spanish Breast Cancer Research Group Scientific Director and the study statistician. The meetings will be performed by teleconference to take these decisions as quickly as possible once the last patient finishes the first cycle of treatment. Other meetings will be considered ad-hoc whenever necessary (i.e when new DLTs appear).

Patients included in the run-in-phase at the same dose than that in the phase II will be considered for the phase II analysis.

Study Drug/Medication:

Eligible patients will be enrolled and treated with:

Pembrolizumab at a dose of 200mg as an intravenous (IV) infusion on day 1 of each 21-day cycle.

in combination with Gemcitabine at a dose of 1,250mg/m2 or 1,000mg/m2 (this dose will be explored in combination with pembrolizumab in the initial exploratory run-in-phase if necessary) as an intravenous (IV) infusion on day 1 and 8 of each 21-day cycle.

Treatment will be repeated on day 1 of each 21-day cycle until objective disease progression, clinical progression (under investigator criteria), unacceptable toxicity, death or withdrawal of consent, whichever occurs first. Patients completing 24 months of uninterrupted treatment with pembrolizumab or 35 administrations of study medication will stop pembrolizumab treatment (though may continue with gemcitabine). Subjects who stop pembrolizumab after 24 months may be eligible for up to one year of additional pembrolizumab treatment if they progress after stopping it.

An initial exploratory run-in-phase will be performed to test the safety of the combination and determine the Recommended Phase II Dose (RP2D) of gemcitabine in combination with fixed doses of pembrolizumab.

Primary Objective:

• Run-in-phase: To determine the Recommended Phase II Dose (RP2D) of gemcitabine in combination with fixed doses of pembrolizumab.

• Phase II: To assess the efficacy of pembrolizumab in combination with gemcitabine in terms of Objective Response Rate (ORR) in patients with HER2-negative ABC.

Primary End-point:

• Run-in-phase: To determine the incidence rate of Dose Limiting Toxicity (DLT) within the first cycle of the combination.

• Phase II: Objective Response Rate (ORR) is defined as Complete Response (CR) plus Partial Response (PR) according to Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1.

Secondary Objectives:

The following secondary objectives will be studied:

• To assess other efficacy measures of the combination in patients included in the phase II (including those in the run-in-phase at the same dose that in the phase II).

• To determine safety and tolerability of the combination in all patients included in the study.

Secondary End-points:

The following secondary end-points will be studied:

• Efficacy:

• Progression-Free Survival (PFS) assessed according to RECIST version 1.1 by the investigator.

• Clinical Benefit Rate (CBR) defined as Complete Response (CR) plus Partial Response (PR) plus Stable Disease (SD) lasting ≥ 24 weeks according to RECIST version 1.1.

• Response Duration (RD) assessed according to RECIST version 1.1.

• Overall Survival (OS). With special interest on long term responders (i.e. alive and without disease progression after 24 months of study treatment).

• Safety will be assessed by standard clinical and laboratory tests (haematology, serum chemistry). Adverse Events (AE) grade will be defined by the NCI CTCAE (National Cancer Institute Common Terminology Criteria for Adverse Events) version 4.0.

Exploratory Objectives:

The following exploratory objectives will be studied in all patients included in the study unless otherwise specified:

• To assess other efficacy measures of the combination based on immune-related (ir) response criteria in patients included in the phase II (including those in the run-in-phase at the same dose that in the phase II).

• To search for tumour tissue and peripheral blood biomarkers of clinical activity.

• To compare biomarkers data from cohorts of healthy volunteers (if available) with data from patients included in the study.

Exploratory End-points:

The following exploratory end-points will be studied:

• Efficacy:

• ORR is defined as immune-related Complete Response (irCR) plus immune-related Partial Response (irPR) according to immune-related RECIST (irRECIST).

• Progression-Free Survival (PFS) assessed according to irRECIST by the investigator.

• Clinical Benefit Rate (CBR) defined as irCR plus irPR plus immune-related Stable Disease (irSD) lasting ≥ 24 weeks according to irRECIST.

• Response Duration (RD) assessed according to irRECIST.

• A set of immune biomarkers will be analysed and correlated with evolution of the disease and efficacy of pembrolizumab in combination with gemcitabine (ORR and other efficacy end-points: PFS, CBR and RD), paying special attention to long term responders.

• This set of immune biomarkers will be compared with those from healthy volunteers (if available).

Study population:

Patients with HER2-negative advanced breast cancer.

Justification of Sample size determination:

A Simon's minimax two-stage design will be employed with the possibility of stopping early due to lack of response. Results from previous studies showed that gemcitabine produced a response rate of around 20%, this will be our expected H0. With the combination of pembrolizumab and gemcitabine, we expect to increase this rate to 35% what will be our H1 (an absolute increase of 15%), with an alpha error of 0.05 and a statistical power of 80%, we will need to include 53 evaluable patients in this trial. The first stage will include 31 evaluable patients, if at least 7 present a response, recruitment will continue to include the 53 evaluable patients. The null hypothesis of H0=20% will be rejected if 16 or more responses are observed in 53 patients.

Statistical Analyses:

Demographics and Baseline Characteristics: Standard descriptive statistics, such as the mean, median, range and proportion, will be used to summarize the patient sample and to estimate parameters of interest.

Safety Analyses: AEs and Serious Adverse Events (SAE) will be reported in frequency tables (overall and by intensity). The safety analysis will be performed in the population that has received at least one dose of any of the study drugs/medications.

Efficacy Analyses: All efficacy endpoints will be evaluated in the Per-protocol and Intent to treat (ITT) populations.

Biomarker analysis:The biomarker analysis will be exploratory and descriptive. For continuous variables, mean, standard deviation, median, minimum and maximum values will be provided. Categorical variables will be summarized by numbers and proportions. Biomarker endpoints will be evaluated in all patients enrolled in the study with available samples.

Study Duration:

The end date of study is date of last patient´s death or the date when there is sufficient data to achieve the primary and secondary objectives and all patients have ended the study treatment, whichever comes first.

Performing exploratory objectives will be independent of the date of the end of the study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 36
• Est. completion date: July 22, 2021
• Est. primary completion date: June 3, 2019
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. The patient has signed and dated the informed consent document and it has been obtained before conducting any procedure specifically for the study.

2. Female = 18 years of age on day of signing informed consent.

3. Histological/cytological confirmation of breast cancer with evidence of advanced disease, not amenable to resection or radiation therapy with curative intent.

4. Documented luminal A, luminal B (HER2-negative) or triple negative disease by immunohistochemistry (IHQ) and/or in situ hybridization (FISH/CISH/SISH) based on local testing on the most recent tumour biopsy defined as follows:

Luminal A: tumour with positive oestrogen receptor (ER) status (=1% of tumour cells with ER expression) and HER2-negative status (IHQ score 0/1+ or negative by in situ hybridization defined as a HER2/chromosome enumeration probe 17 (CEP17) ratio < 2 or for single probe assessment a HER2 copy number < 4) and high progesterone receptor (PgR) (= 20% of tumour cells with PgR expression) and low Ki67 (< 14%).

Luminal B (HER2-negative): tumour with positive ER status (=1% of tumour cells with ER expression) and HER2-negative status (IHQ score 0/1+ or negative by in situ hybridization defined as a HER2/CEP17 ratio < 2 or for single probe assessment a HER2 copy number < 4) and either low or negative PgR (< 20% of tumour cells with PgR expression) and/or high Ki67 (= 14%).

Triple negative: tumour with negative hormone receptor status (<1% of tumour cells with ER and PgR expression) and HER2-negative status (IHQ score 0/1+ or negative by in situ hybridization defined as a HER2/CEP17 ratio < 2 or for single probe assessment a HER2 copy number < 4).

5. Have at least one unidimensionally measurable lesion by RECIST 1.1.

6. Patient agrees to the collection of a metastatic tumor sample (biopsy) at the time of inclusion and at progression (whenever possible).

7. Have a performance status of 0, 1 or 2 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale.

8. Demonstrate adequate organ function as follows (all screening labs should be performed within 7 days of study treatment initiation):

Bone marrow:

Absolute Neutrophil Count (ANC) = 1,500/mm3 (1.5x109/l) Platelets = 100,000/mm3 (100x109/l) Hemoglobin = 9g/dl or = 5.6 mmol/l without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)

Hepatic:

Serum total bilirubin = 1.5 x Upper Limit of Normal (ULN) Alkaline Phosphatase = 2.5 x ULN Aspartate aminotransferase (AST) (SGOT) and Alanine aminotransferase (ALT) (SGPT) = 2.5 x ULN or = 5 x ULN for patients with liver metastases Albumin = 2.5 g/dl

Renal:

Serum creatinine = 1.5 x ULN or creatinine clearance = 60 ml/min for patients with creatinine levels > 1.5 x ULN

Coagulation:

International Normalized Ratio (INR) or Prothrombin Time (PT) = 1.5 x ULN unless patient is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants.

Activated Partial Thromboplastin Time (aPTT) = 1.5 x ULN unless patient is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants.

9. Prior treatment with anthracyclines and taxanes (unless clinically contraindicated) and two or more prior lines of hormone therapy in hormone receptor positive disease.

10. At least 3 months life expectancy.

11. Patient of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study drug/medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.

12. Patients of childbearing potential (see section 4.4. for definition) must be willing to use an adequate method of contraception as outlined in Section 4.4. - Contraception, for the course of the study through 120 days after the last dose of study medication.

Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.

13. Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests and other study procedures.

Exclusion Criteria:

1. HER2-positive disease by immunohistochemistry or in situ hybridation (FISH-SISH-CISH).

2. Patient is currently participating or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of study drug/medication.

3. Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1 or who has not recovered (i.e., = grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier.

4. Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., = grade 1 or at baseline) from adverse events due to a previously administered agent.

• Note: Patients with = grade 2 neuropathy are an exception to this criterion and may qualify for the study.

• Note: If patient received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.

5. Has received prior therapy with an anti-Programmed death-1 (PD), anti-PD-L1, or anti-PD-L2 agent.

6. Has received a live vaccine within 30 days of planned start of study therapy.

o Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however, intranasal influenza vaccines (e.g., Flu-Mist) are live attenuated vaccines, and are not allowed.

7. Has hypersensitivity to pembrolizumab, gemcitabine or any of theirs excipients.

8. Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Patients with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and all neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment. This exception does not include carcinomatous meningitis which is excluded regardless of clinical stability.

9. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug/medication.

10. Has an active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.

11. Has a current or prior malignancy within the previous 5 years (other than breast cancer or adequately treated basal cell or squamous cell carcinoma of the skin or in-situ carcinoma of the cervix).

12. Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis.

13. Has an active infection requiring systemic therapy.

14. Has a known history of active Tuberculosis Bacillus (TB) or Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies) or a known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., hepatitis C virus (HCV) RNA [qualitative] is detected).

15. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the patient's participation for the full duration of the trial, or is not in the best interest of the patient to participate, in the opinion of the treating investigator.

16. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.

17. Patient is pregnant or breastfeeding, or expecting to conceive within the projected duration of the trial, starting with the baseline visit through 120 days after the last dose of trial treatment.

Related Conditions & MeSH terms

• Advanced Breast Cancer
• Breast Neoplasms

Intervention

Drug:
• Pembrolizumab
Pembrolizumab at a dose of 200mg as an intravenous (IV) 30 minutes infusion on day 1 of each 21-day cycle. Treatment will be repeated on day 1 of each 21-day cycle until objective disease progression, clinical progression (under investigator criteria), unacceptable toxicity, death or withdrawal of consent, whichever occurs first. Patients completing 24 months of uninterrupted treatment with pembrolizumab or 35 administrations of study medication will stop pembrolizumab treatment (though may continue with gemcitabine). Subjects who stop pembrolizumab after 24 months may be eligible for up to one year of additional pembrolizumab treatment if they progress after stopping it.
• Gemcitabine
Gemcitabine at a dose of 1,250mg/m2 as an intravenous (IV) 60 minutes infusion on day 1 and 8 of each 21-day cycle. Treatment will be repeated on day 1 of each 21-day cycle until objective disease progression, clinical progression (under investigator criteria), unacceptable toxicity, death or withdrawal of consent, whichever occurs first.

Locations

Country	Name	City	State
Spain	Centro Oncológico de Galicia	A Coruña
Spain	Institut Català d'Oncologia. Hospital Universitario Germans Trias i Pujol	Badalona	Barcelona
Spain	Hospital Universitario Virgen de la Arrixaca	El Palmar	Murcia
Spain	Hospital Universitario de Canarias	La Laguna	Canarias
Spain	Hospital Clínico Universitario San Carlos	Madrid
Spain	Hospital Universitario Ramón y Cajal	Madrid
Spain	Clínica Universitaria de Navarra	Pamplona	Navarra
Spain	Hospital Universitario Virgen de la Macarena	Sevilla
Spain	Hospital Clínico Universitario de Zaragoza "Lozano Blesa"	Zaragoza

Sponsors (2)

Lead Sponsor	Collaborator
Spanish Breast Cancer Research Group	Merck Sharp & Dohme LLC

Country where clinical trial is conducted

Spain, 

References & Publications (2)

de la Cruz-Merino L, Gion M, Cruz J, Alonso-Romero JL, Quiroga V, Moreno F, Andres R, Santisteban M, Ramos M, Holgado E, Cortes J, Lopez-Miranda E, Cortes A, Henao F, Palazon-Carrion N, Rodriguez LM, Ceballos I, Soto A, Puertes A, Casas M, Benito S, Chies — View Citation

de la Cruz-Merino L, Gion M, Cruz-Jurado J, Quiroga V, Andres R, Moreno F, Alonso-Romero JL, Ramos M, Holgado E, Cortes J, Lopez-Miranda E, Henao-Carrasco F, Palazon-Carrion N, Rodriguez LM, Ceballos I, Casas M, Benito S, Chiesa M, Bezares S, Caballero R, — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Dose Limiting Toxicity (DLT) Within the First Cycle	DLT was defined as the occurrence of any of the following adverse events (AE) or abnormal laboratory value (graded according to the NCI Common Terminology Criteria for AE (CTCAE) version 4.0), assessed as possibly, probably or definitively related to study drug/medication, occurring within the first cycle of study treatment: any Grade 4 thrombocytopenia or neutropenia lasting > 7 days; episcleritis, uveitis, or iritis of Grade 2 or higher, any Grade 4 toxicity, any Grade 3 toxicity EXCLUDING: nausea, vomiting, or diarrhea controlled by medical intervention within 72 hours, grade 3 rash in the absence of desquamation, no mucosal involvement, does not require steroids, and resolves to Grade 1 by the next scheduled dose of pembrolizumab, transient Grade 3 Aspartate Transaminase (AST) or Alanine Transaminase (ALT) elevation, defined as no more than 3 days with or without steroid use, discontinuation or delay of more than 2 weeks of any study drug/medication due to treatment-related AE.	Up to cycle 1
Primary	Recommended Phase II Dose (RP2D) of Gemcitabine in Combination With Pembrolizumab	The RP2D was decided by the internal committee taken into consideration the information obtained in the study and based on the number of DLT.	Up to cycle 1
Primary	Objective Response Rate (ORR)	Tumor response was assessed using Response Evaluation Criteria In Solid Tumors Criteria (RECIST 1.1). ORR is defined as the percentage of patients with a Complete Response (CR) or Partial Response (PR) out of the patients from the efficacy population. Per RECIST, CR is defined as the disappearance of all target lesions; PR is defined as an >=30% decrease in the sum of the longest diameter of target lesions.	Through study treatment, and average of 3 months
Secondary	Progression-Free Survival (PFS)	Tumor response was assessed using Response Evaluation Criteria In Solid Tumors Criteria (RECIST 1.1). PFS is defined as the time from enrollment to the first documented progression disease (PD), or death from any cause, whichever occurs first. PD is defined using RECIST, as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions	Through study treatment, and average of 3 months
Secondary	Clinical Benefit Rate (CBR)	Tumor response was assessed using Response Evaluation Criteria In Solid Tumors Criteria (RECIST 1.1) criteria. CBR was defined as the percentage of patients with a Complete Response (CR) or Partial Response (PR) plus stable disease (SD) out of the efficacy population. Per RECIST, CR is defined as the disappearance of all target lesions; PR is defined as an >=30% decrease in the sum of the longest diameter of target lesions; SD is defined as a failure to meet criteria for CR or PR in the absence of progressive disease. Overall Response (OR) = CR + PR.	Through study treatment, and average of 3 months
Secondary	Clinical Benefit Rate (CBR) at Least 24 Weeks	Tumor response was assessed using Response Evaluation Criteria In Solid Tumors Criteria (RECIST 1.1) criteria. CBR was defined as the percentage of patients with a Complete Response (CR) or Partial Response (PR) plus stable disease (SD) lasting at least 24 months out of the efficacy population. Per RECIST, CR is defined as the disappearance of all target lesions; PR is defined as an >=30% decrease in the sum of the longest diameter of target lesions; SD is defined as a failure to meet criteria for CR or PR in the absence of progressive disease lasting at least 24 months. Overall Response (OR) = CR + PR.	24 weeks
Secondary	Response Duration (RD)	Tumor response was assessed using Response Evaluation Criteria In Solid Tumors Criteria (RECIST 1.1) criteria. RD was defined as the time from the first documentation of objective tumor response (complete response (CR) or partial response (PR)) to the first documented progressive disease (PD), or to death due to any cause, whichever occurs first. Per RECIST, CR is defined as the disappearance of all target lesions; PR is defined as an >=30% decrease in the sum of the longest diameter of target lesions; PD is defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions	Through study treatment, and average of 3 months
Secondary	Overall Survival (OS)	OS is defined as the time from the date of enrollment to the date of death from any cause.	Up to 2 years
Secondary	The Number of Participants Who Experienced Adverse Events (AE) Related to Study Treatment	Safety assessments were performed at baseline and during the study: Vital signs assessments (blood pressure, pulse and body temperature), Laboratory assessments (hemoglobin, platelet count, White Blood Cell (WBC), Absolute Neutrophil Count (ANC) and Absolute Lymphocyte Count (ALC), albumin, alkaline phosphatase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin, serum creatinine, creatinine clearance (for patients with creatinine levels > 1.5 x ULN), glucose and urea, International Normalized Ratio (INR)/ Prothrombin time (PT) and activated partial thromboplastin time (aPTT), total or free triiodothyronine (T3 or FT3), free thyroxine (FT4) and Thyroid-stimulating hormone (TSH)) and Urinalysis. A baseline standard 12-lead electrocardiogram (ECG) was mandatory. AEs were graded according to NCI-CTCAE (National Cancer Institute Common Terminology Criteria for Adverse Events) version 4.03.	Through study treatment, and average of 3 months
Secondary	Immune-related Objective Response Rate (irORR)	Tumor response was assessed using Immune-Related Response Evaluation Criteria In Solid Tumors Criteria (irRECIST v 1.0). irORR is defined as the percentage of patients with a Immune-Related Complete Response (irCR) or Immune-Related Partial Response (irPR) out of the patients from the efficacy population. Per irRECIST, irCR is defined as the disappearance of all measurable and non-measurable lesions, and lymph nodes must decrease to < 10 mm in short axis; irPR is defined as an >=30% decrease in total measured tumor burden relative to baseline; Immune-Related Overall Response (irOR) = irCR + irPR.	Through study treatment, and average of 3 months
Secondary	Immune-related Progression-Free Survival (irPFS)	Tumor response was assessed using Immune-Related Response Evaluation Criteria In Solid Tumors Criteria (irRECIST v 1.0). irPFS was defined as the time from enrollment to the first documented progressive disease (PD), or death from any cause, whichever occurs first. PD is defined by irRECIST, as a 20% increase and minimum 5 mm absolute increase in total measured tumor burden compared with nadir, or a measurable increase in a non-target lesion, or the appearance of new lesions.	Through study treatment, and average of 3 months
Secondary	Immune Related Clinical Benefit Rate (irCBR)	Tumor response was assessed using Immune-Related Response Evaluation Criteria In Solid Tumors Criteria (irRECIST v 1.0). irCBR was defined as the percentage of patients with a Immune Related Complete Response (irCR) or Immune Related Partial Response (irPR) plus Immune Related Stable Disease (irSD) out of the efficacy population. Per irRECIST, irCR is defined as the disappearance of all measurable and non-measurable lesions, and lymph nodes must decrease to < 10 mm in short axis; irPR is defined as an >=30% decrease in total measured tumor burden relative to baseline; irSD is defined as a failure to meet criteria for irCR or irPR in the absence of progressive disease.	Through study treatment, and average of 3 months
Secondary	Immune Related Clinical Benefit Rate (irCBR) at Least 24 Weeks	Tumor response was assessed using Immune-Related Response Evaluation Criteria In Solid Tumors Criteria (irRECIST v 1.0). irCBR was defined as the percentage of patients with a Immune Related Complete Response (irCR) or Immune Related Partial Response (irPR) plus Immune Related stable disease (irSD) lasting at least 24 months out of the efficacy population. Per irRECIST, irCR is defined as the disappearance of all measurable and non-measurable lesions, and lymph nodes must decrease to < 10 mm in short axis; irPR is defined as an >=30% decrease in total measured tumor burden relative to baseline; irSD is defined as a failure to meet criteria for irCR or irPR in the absence of progressive disease at least 24 weeks.	Through study treatment, and average of 3 months
Secondary	Immune Related Response Duration (irRD)	Tumor response was assessed using Immune-Related Response Evaluation Criteria In Solid Tumors Criteria (irRECIST v 1.0). irRD was defined as the time from the first documentation of objective tumor response (immune related complete response (irCR) or immune related partial response (irPR)) to the first documented immune related progressive disease (irPD), or to death due to any cause, whichever occurs first. Per RECIST, irCR is defined as the disappearance of all measurable and non-measurable lesions, and lymph nodes must decrease to < 10 mm in short axis; irPR is defined as an >=30% decrease in total measured tumor burden relative to baseline; irPD is defined as a 20% increase and minimum 5 mm absolute increase in total measured tumor burden compared with nadir, or a measurable increase in a non-target lesion, or the appearance of new lesions.	Through study treatment, and average of 3 months

External Links

•   GEICAM is a Spanish Breast Cancer Research Group